# Effectiveness of adding inspiratory muscle training to a cardiac rehabilitation program in people with acute myocardial infarction revascularized by percutaneous coronary intervention (CARDIOINSPIRE): Study protocol for a randomized controlled trial

**Authors:** Jose M. Zuazagoitia-Lama-Noriega, A. M. Gómez-González, Jose A. Moral-Munoz, Mansueto Neto, Mansueto Neto, Mansueto Neto

PMC · DOI: 10.1371/journal.pone.0343947 · 2026-03-10

## TL;DR

This study will test if adding breathing exercises to heart rehab improves recovery in patients who had a heart attack and stent placement.

## Contribution

This is the first trial to evaluate the impact of inspiratory muscle training on biopsychosocial outcomes in post-PCI AMI patients.

## Key findings

- Improvements in cardiorespiratory fitness and inspiratory muscle strength are expected.
- The study will clarify how breathing training affects psychological and social recovery outcomes.
- Results may guide future cardiac rehabilitation protocols to include IMT.

## Abstract

This study aims to analyze the effectiveness of adding inspiratory muscle training (IMT) to a cardiac rehabilitation program (CRP) in people with acute myocardial infarction (AMI) revascularized by percutaneous coronary intervention (PCI) after 16 sessions. The biopsychosocial profile and the sex differences of this population will also be evaluated.

Triple-blind, parallel-group, low-risk randomized controlled trial.

72 patients diagnosed with AMI will be enrolled and randomly assigned to two groups. The control group will complete the usual CRP with the addition of IMT at 5% of the maximal inspiratory pressure (MIP) (sham load). The intervention group will perform the same CRP but will add an IMT program at 70% of MIP. Outcomes will be collected at baseline and post-intervention. The main outcome will be cardiorespiratory fitness (CF) measured in metabolic equivalent of task (MET), secondary outcomes will be MIP, maximal expiratory pressure, peripheral muscle strength, dyspnea, social support, anxiety, depression, coping with the disease, sexual dysfunction, quality of life (QoL), sleep quality, eating habits, and body composition. Descriptive statistics will summarize baseline data, and influential outliers will be managed via winsorization or exclusion, confirmed by sensitivity analyses. A mixed-design ANOVA will evaluate differential changes over time. Depending on attrition rates, missing data will be addressed using either complete case analysis (<5%) or multiple imputation with an intention-to-treat approach (>5%).

According to recent literature, improvements in CF and MIP are expected. For the rest of the outcomes, data are currently limited, inconclusive or lacking. We hypothesize that changes in CF may affect the rest of the outcomes and, in our opinion, IMT at 70% of the MIP will significantly improve CF.

If the expected benefits are observed, the results may recommend including IMT as a fundamental component of a CRP in our study population.

Registered prospectively at ClinicalTrials.gov (NCT06681740) Version 4.

## Linked entities

- **Diseases:** acute myocardial infarction (MONDO:0004781)

## Full-text entities

- **Genes:** CRP (C-reactive protein) [NCBI Gene 1401] {aka PTX1}
- **Diseases:** Ischemia (MESH:D007511), CF (MESH:D012640), myocarditis (MESH:D009205), chronic obstructive pulmonary disease (MESH:D029424), fatigue (MESH:D005221), arrhythmias (MESH:D001145), obesity (MESH:D009765), respiratory (MESH:D012131), Anxiety and Depression (MESH:D001007), cardiopulmonary arrest (MESH:D006323), angina (MESH:D000787), diabetes mellitus (MESH:D003920), sexual dysfunction (MESH:D012735), stable angina (MESH:D060050), breathlessness (MESH:D004417), muscle (MESH:D019042), pain (MESH:D010146), dyslipidemia (MESH:D050171), unstable angina (MESH:D000789), cognitive deficits (MESH:D003072), coronary artery disease (MESH:D003324), heart disease (MESH:D006331), HF (MESH:D006333), depression (MESH:D003866), obstructive sleep apnea (MESH:D020181), erectile dysfunction (MESH:D007172), Ischemic Heart Disease (MESH:D017202), AMI (MESH:D009203), cardiovascular disease (MESH:D002318), hypertension (MESH:D006973), death (MESH:D003643), MIP (MESH:D003668), pericarditis (MESH:D010493)
- **Chemicals:** H2O. (MESH:D014867), carbon (MESH:D002244), O2 (MESH:D010100), IMT (-), olive oil (MESH:D000069463)
- **Species:** Homo sapiens (human, species) [taxon 9606]

## Figures

3 figures with captions in the complete paper: https://tomesphere.com/paper/PMC12974859/full.md

---
Source: https://tomesphere.com/paper/PMC12974859